The role of paliperidone extended release for the treatment of bipolar disorder

References

• MerikangasKRAkiskalHSAngstJLifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replicationArch Gen Psychiatry200764554355217485606
   PubMed Web of Science ®Google Scholar
• MerikangasKRJinRHeJPPrevalence and correlates of bipolar spectrum disorder in the world mental health survey initiativeArch Gen Psychiatry201168324125121383262
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders4th ed Text revisionWashington, DCAmerican Psychiatric Association2000
   Google Scholar
• OstacherMJPerlisRHNierenbergAAImpact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Am J Psychiatry2010167328929720008948
   PubMed Web of Science ®Google Scholar
• PerlisRHOstacherMJMiklowitzDJClinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD studyJ Clin Psychiatry201071329630320331931
   PubMed Web of Science ®Google Scholar
• PerlisRHUherROstacherMAssociation between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorderArch Gen Psychiatry201168435136021135313
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationPractice guideline for the treatment of patients with bipolar disorder (revision)Am J Psychiatry2002159Suppl 4150
   Web of Science ®Google Scholar
• SuppesTDennehyEBHirschfeldRMThe Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorderJ Clin Psychiatry200566787088616013903
   PubMed Web of Science ®Google Scholar
• YathamLNKennedySHSchafferACanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009Bipolar Disord200911322525519419382
   PubMed Web of Science ®Google Scholar
• CiprianiABarbuiCSalantiGComparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysisLancet201137897991306131521851976
   PubMed Web of Science ®Google Scholar
• TohenMZarateCAJrHennenJThe McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrenceAm J Psychiatry2003160122099210714638578
   PubMed Web of Science ®Google Scholar
• LingamRScottJTreatment non-adherence in affective disordersActa Psychiatr Scand2002105316417211939969
   PubMed Web of Science ®Google Scholar
• VietaESanchez-MorenoJAcute and long-term treatment of maniaDialogues Clin Neurosci200810216517918689287
   PubMedGoogle Scholar
• Invega™ (paliperidone) extended-release tablets [package insert]Titusville, NJ2007
   Google Scholar
• LeysenJEJanssenPMMegensAASchotteARisperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activityJ Clin Psychiatry199455 Suppl5127520908
   PubMed Web of Science ®Google Scholar
• SchotteAJanssenPFGommerenWRisperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindingPsychopharmacology (Berl)19961241–257738935801
   PubMed Web of Science ®Google Scholar
• RichelsonESouderTBinding of antipsychotic drugs to human brain receptors focus on newer generation compoundsLife Sci2000681293911132243
   PubMed Web of Science ®Google Scholar
• MegensAAAwoutersFHSchotteASurvey on the pharmacodynamics of the new antipsychotic risperidonePsychopharmacology (Berl)199411419237531353
   PubMed Web of Science ®Google Scholar
• KarlssonPDenckerENybergSPharmacokinetics, dopamine (D2) and serotonin 5HT(2A) receptor occupancy of paliperidone in healthy subjectsClin Pharmacol Ther200579P7474
   Web of Science ®Google Scholar
• MiyamotoSDuncanGEMarxCELiebermanJATreatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugsMol Psychiatry20051017910415289815
   PubMed Web of Science ®Google Scholar
• Corena-McLeod MdelPOliverosACharlesworthCPaliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expressionBrain Res20083123381918657526
   PubMed Web of Science ®Google Scholar
• VermeirMNaessensIRemmerieBAbsorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humansDrug Metab Dispos200836476977918227146
   PubMed Web of Science ®Google Scholar
• CletonARossenuSVermeulenAA pharmacokinetic model to document the interconversion between paliperidone’s enantiomers [abstract]Clin Pharmacol Ther200679255
   Web of Science ®Google Scholar
• RossenuSvan de VlietICletonAA pharmacokinetic model to document the interconversion between the enantiomers of paliperidone [abstract]Biol Psychiatry2006598223S
   Web of Science ®Google Scholar
• BoomSThyssenACrauwelsHThe influence of hepatic impairment on the pharmacokinetics of paliperidoneInt J Clin Pharmacol Ther2009471060661619825324
   PubMed Web of Science ®Google Scholar
• DunbarFChuePFuDHuangQFrancMCohenNImpact of CYP2D6 metabolizer phenotype on the safety profile of paliperidone ERThe Society of Biological Psychiatry 62nd Annual Scientific ConventionSan Diego, CaliforniaMay 17–19, 2007
   Google Scholar
• CletonARossenuSBoomSEvaluation of the pharmacokinetics of paliperidone extended release tablets in healthy elderly subjectsPresented at the 3rd Pharmaceutical Sciences World CongressAmsterdam, The Netherlands2007
   Google Scholar
• ChiritaVA safety and pharmacokinetic study of ER OROS paliperidone in pediatric patients with schizophrenia, schizoaffective disorder, or schizophreniform disorderClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2011 [updated June 6, 2011]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00796081. NLM identifier: NCT00796081Accessed March 16, 2012
   Google Scholar
• BerwaertsJCletonAHerbenVThe effects of paroxetine on the pharmacokinetics of paliperidone extended-release tabletsPharmacopsychiatry200942415816319585395
   PubMed Web of Science ®Google Scholar
• ThyssenACletonATalluriKNo pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjectsHum Psychopharmacol200924753253919693799
   PubMed Web of Science ®Google Scholar
• De LeonJWynnGSNThe pharmacokinetics of paliperidone versus risperidonePsychosomatics2010511808820118446
   PubMed Web of Science ®Google Scholar
• BerwaertsJXuHNuamahILimPHoughDEvaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response studyJ Affect Disord20121361–2e51e6020624657
   PubMed Web of Science ®Google Scholar
• VietaENuamahIFLimPA randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorderBipolar Disord201012323024320565430
   PubMed Web of Science ®Google Scholar
• BerwaertsJLaneRNuamahIFPaliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled studyJ Affect Disord20111291–325226020947174
   PubMed Web of Science ®Google Scholar
• CanusoCMBattistiWPPaliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar maniaExpert Opin Pharmacother201011152557256720854185
   PubMed Web of Science ®Google Scholar